Our mission: To develop new therapies for type 1 and type 2 diabetes
Fairbanks Pharmaceuticals is developing transformative diabetes therapies that address the underlying cause of diabetes: loss of insulin from beta cells.
Learn about Fairbanks Pharmaceuticals
- Fairbanks was awarded a Phase II $1.83M SBIR grant in June, 2018. Read more
- Scroll through other recent news in our blog.
- Read about the science behind our work.
- Read a summary of the positive niche assessment of Fairbanks’ potential in NIH-funded profile
- Background on CEO Alan Schneyer here and here.
- Sign up to the right to receive email updates with our latest news.
Fairbanks CEO Alan Schneyer with Lab and Animal Technician Alexa Lopez